Treatment of Ulcerative Colitis

Current treatment options for patients who fail steroids or wish to taper off steroids include a number of systemic immunosuppressants, such as thiopurines and biologics. Conventional cyclosporine use is limited to patients failing intravenous steroids. With its potential improved safety profile, there is a possibility ST-0529 could be introduced earlier in the treatment paradigm with the goals of minimizing exposure to steroids as well as avoiding or delaying use of systemic immunosuppressants.

ST-0529 is currently in clinical research and is not approved as safe and effective for use by the FDA, or any Regulatory agency.